Literature DB >> 16575327

Dexamethasone and enhancing solitary cerebral mass lesions: alterations in perfusion and blood-tumor barrier kinetics shown by magnetic resonance imaging.

Iain D Wilkinson1, David A Jellineck, David Levy, Frederik L Giesel, Charles A J Romanowski, Barbara-Ann Miller, Paul D Griffiths.   

Abstract

OBJECTIVE: Glucocorticoid analogues are often administered to patients with intracranial space-occupying lesions. Clinical response can be dramatic, but the neurophysiological response is not well documented. This study sought to investigate the blood-lesion barrier, blood-brain barrier, and cerebral perfusion characteristics of patients who have undergone such therapy using magnetic resonance imaging.
METHODS: Seventeen patients with intracranial mass-enhancing lesions underwent magnetic resonance imaging before and after 3 days of high-dose dexamethasone therapy. Assessments of blood-lesion barrier and blood-brain barrier integrity were based on a dynamic T1-weighted exogenous contrast technique that yielded the normalized maximal change in contrast uptake (T1-uptake). Perfusion was assessed using a dynamic T2*-weighted exogenous contrast technique to yield relative regional cerebral blood volume and first-moment mean transit time. Comparisons were made in T1-uptake, regional cerebral blood volume, and first-moment mean transit time of both enhancing lesion and contralateral normal-appearing white matter (CNAWM) obtained before and after dexamethasone.
RESULTS: Significant reduction in T1-uptake was observed (19% decrease, P < 0.005) within enhancing pathological tissue, whereas no significant alteration was detected in CNAWM. Regional cerebral blood volume was significantly reduced in both enhancing tissue (28% decrease, P < 0.005) and in CNAWM (20% decrease, P < 0.001). Bolus first-moment mean transit time significantly increased (2.0 s prolongation, P < 0.05) in CNAWM, whereas there was no significant change (1.4 s prolongation, P > 0.05) within enhancing tissue.
CONCLUSION: Glucocorticoid-analogue therapy not only affects the permeability of the blood-lesion barrier and lesion blood volume but also affects blood flow within normal-appearing contralateral parenchyma. There is a need for controls in steroid therapy in magnetic resonance imaging studies, which involve assessments of cerebrovascular function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16575327     DOI: 10.1227/01.NEU.0000204873.68395.A0

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  9 in total

Review 1.  Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy.

Authors:  Anwar R Padhani; Aftab Alam Khan
Journal:  Target Oncol       Date:  2010-04-11       Impact factor: 4.493

2.  Prognostic value of blood flow estimated by arterial spin labeling and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas.

Authors:  Mandy Kim Rau; Christian Braun; Marco Skardelly; Jens Schittenhelm; Frank Paulsen; Benjamin Bender; Ulrike Ernemann; Sotirios Bisdas
Journal:  J Neurooncol       Date:  2014-08-27       Impact factor: 4.130

Review 3.  Clinical Relevance of Steroid Use in Neuro-Oncology.

Authors:  K Ina Ly; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 4.  Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?

Authors:  Martin Zweifel; Anwar R Padhani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

5.  Relative cerebral blood volume from dynamic susceptibility contrast perfusion in the grading of pediatric primary brain tumors.

Authors:  Chang Y Ho; Jeremy S Cardinal; Aaron P Kamer; Stephen F Kralik
Journal:  Neuroradiology       Date:  2014-12-13       Impact factor: 2.804

6.  Time-delayed contrast-enhanced MRI improves detection of brain metastases: a prospective validation of diagnostic yield.

Authors:  Or Cohen-Inbar; Zhiyuan Xu; Blair Dodson; Tanvir Rizvi; Christopher R Durst; Sugoto Mukherjee; Jason P Sheehan
Journal:  J Neurooncol       Date:  2016-08-27       Impact factor: 4.130

7.  DCE-MRI assessment of the effect of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme on tumor vasculature in patients with nasopharyngeal carcinomas.

Authors:  Wei-Hua Liao; Li-Fang Yang; Xiao-Yu Liu; Gao-Feng Zhou; Wu-Zhong Jiang; Bob-Lei Hou; Lun-Quan Sun; Ya Cao; Xiao-Yi Wang
Journal:  BMC Cancer       Date:  2014-11-18       Impact factor: 4.430

Review 8.  Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review.

Authors:  Anna K Heye; Ross D Culling; Maria Del C Valdés Hernández; Michael J Thrippleton; Joanna M Wardlaw
Journal:  Neuroimage Clin       Date:  2014-09-10       Impact factor: 4.881

Review 9.  Drug interactions at the blood-brain barrier: fact or fantasy?

Authors:  Sara Eyal; Peng Hsiao; Jashvant D Unadkat
Journal:  Pharmacol Ther       Date:  2009-04-22       Impact factor: 13.400

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.